N-acetylcysteine improves coronary and peripheral vascular function

Author(s): Andrews NP, Prasad A, Quyyumi AA

Abstract

Objectives: We investigated whether N-acetylcysteine (NAC), a reduced thiol that modulates redox state and forms adducts of nitric oxide (NO), improves endothelium-dependent vasomotion.

Background: Coronary atherosclerosis is associated with endothelial dysfunction and reduced NO activity.

Methods: In 16 patients undergoing cardiac catheterization, seven with and nine without atherosclerosis, we assessed endothelium-dependent vasodilation with acetylcholine (ACH) and endothelium-independent vasodilation with nitroglycerin (NTG) and sodium nitroprusside (SNP) before and after intracoronary NAC. In 14 patients femoral vascular responses to ACH, NTG and SNP were measured before and after NAC.

Results: Intraarterial NAC did not change resting coronary or peripheral vascular tone. N-acetylcysteine potentiated ACH-mediated coronary vasodilation; coronary blood flow was 36 +/- 11% higher (p < 0.02), and epicardial diameter changed from -1.2 +/- 2% constriction to 4.7 +/- 2% dilation after NAC (p = 0.03). Acetylcholine-mediated femoral vasodilation was similarly potentiated by NAC (p = 0.001). Augmentation of the ACH response was similar in patients with or without atherosclerosis. N-acetylcysteine did not affect NTG-mediated vasodilation in either the femoral or coronary circulations and did not alter SNP responses in the femoral circulation. In contrast, coronary vasodilation with SNP was significantly greater after NAC (p < 0.05).

Conclusions: Thiol supplementation with NAC improves human coronary and peripheral endothelium-dependent vasodilation. Nitroglycerin responses are not enhanced, but SNP-mediated responses are potentiated only in the coronary circulation. These NO-enhancing effects of thiols reflect the importance of the redox state in the control of vascular function and may be of therapeutic benefit in treating acute and chronic manifestations of atherosclerosis.

Similar Articles

Diabetes and the risk of heart failure

Author(s): Dhingra R, Vasan RS

Pathophysiology of myocardial reperfusion

Author(s): Fox KA, Bergmann SR, Sobel BE

Chronic pharmacological preconditioning against ischemia

Author(s): Luca MC, Liuni A, Muxel S, Münzel T, Forconi S, et al.

Myocardial fatty acid metabolism in health and disease

Author(s): Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC

FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress

Author(s): Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE

FoxO, autophagy, and cardiac remodeling

Author(s): Ferdous A, Battiprolu PK, Ni YG, Rothermel BA, Hill JA

The FoxO family in cardiac function and dysfunction

Author(s): Ronnebaum SM, Patterson C

Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice

Author(s): Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, et al.

Diabetes triggers a PARP1 mediated death pathway in the heart through participation of FoxO1

Author(s): Puthanveetil P, Zhang D, Wang Y, Wang F, Wan A, et al.

Altered acetylcholine and norepinephrine concentrations in diabetic rat hearts

Author(s): Akiyama N, Okumura K, Watanabe Y, Hashimoto H, Ito T, et al.

Glucose for the heart

Author(s): Depre C, Vanoverschelde JL, Taegtmeyer H

Hibernating myocardium

Author(s): Wijns W, Vatner SF, Camici PG

Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study

Author(s): Leung AA, Eurich DT, Lamb DA, Majumdar SR, Johnson JA, et al.

Phosphatases at the heart of FoxO metabolic control

Author(s): Tremblay ML, Giguère V

Adiponectin in the heart and vascular system

Author(s): Ding M, Rzucidlo EM, Davey JC, Xie Y, Liu R, et al.

The role of FoxO in the regulation of metabolism

Author(s): Gross DN, van den Heuvel AP, Birnbaum MJ

FoxO transcription factors; Regulation by AKT and 14-3-3 proteins

Author(s): Tzivion G, Dobson M, Ramakrishnan G

Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction

Author(s): Parisi Q, Biondi-Zoccai GG, Abbate A, Santini D, Vasaturo F, et al.

Silent information regulator 1 protects the heart from ischemia/reperfusion

Author(s): Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, et al.

Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase

Author(s): Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, et al.

Oxidative stress, nitric oxide, and diabetes

Author(s): Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, et al.

Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure

Author(s): Mehra A, Shotan A, Ostrzega E, Hsueh W, Vasquez-Johnson J, et al.

Influence of diabetes mellitus on heart failure risk and outcome

Author(s): Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, et al.

Forkhead transcription factors coordinate expression of myocardial KATP channel subunits and energy metabolism

Author(s): Philip-Couderc P, Tavares NI, Roatti A, Lerch R, Montessuit C, et al.

An essential role of the JAK-STAT pathway in ischemic preconditioning

Author(s): Xuan YT, Guo Y, Han H, Zhu Y, Bolli R

Preconditioning the diabetic heart: the importance of Akt phosphorylation

Author(s): Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM